Drug Development

By the numbers: 2-year tally of Celgene’s biotech partnership deals tops $3B in cash

Bob Hugin and his busy dealmaking wiz George Golumbeski have positioned Celgene as an industry-leading wheeler and dealer.

$1 billion to partner with Juno on CAR-T? OK. $200 million in cash to rewrite a pact with Agios? They’ll take that. Another $450 million to partner with AstraZeneca on its checkpoint? No problemo. As bigger companies fretted over the valuations they were seeing in the biotech boom, Celgene’s executive team were struck by the opportunities. “If we see them, we’re going to go after them at the right time,” Celgene CEO Bob Hugin told me last summer, after grabbing Receptos for its immunology pipeline for $7.2 billion.

Any doubts on that score should have been laid to rest with their latest deal to marry up with Jounce for $261 million in an upfront and equity investment, a blend that Celgene has long liked. Golumbeski is also a known fan of the option agreement.

To give you a better idea of just how prolific Celgene has been in recent years, we asked RBC’s Michael Yee if we could share his chart collection of Celgene’s partnership deals. To put this in some perspective, we know from the company’s statements that it has committed $3.2 billion in cash for Yee’s list of pacts just over the past two years.

That’s more than what Gilead spent for all of R&D in 2015.

There’s also at least $5 billion in milestones to consider (Celgene doesn’t release every figure tied to a deal). Interestingly, that ratio of cash to milestones helps illustrate why biotech companies are so joyful when they see Golumbeski at the deal table. It also doesn’t hurt that Celgene typically leaves its partners in charge of the innovation development work needed to be done.

Here’s a list of select Celgene partnered programs:

Jounce Therapeutics Jul-16 JTX-2011 + successor Immuno‐oncology
Nurix Sep‐15 Small Molecule Drug Discovery Oncology, Inflammation, Immunology
Epizyme Jul‐15 (+1) 3 Predefined Targets; DOTL1 To be Determined; MLL
Juno Therapeutics Jun‐15 CD19 and CD22 CAR‐T Cancer, Autoimmune Diseases
Lycera Jun‐15 LYC‐30937 Immuno‐oncology
AstraZeneca Apr‐15 MEDI4736 Cancer Hematology
Zymeworks Jan‐15
Sutro Biopharma Oct-14 (+1) Antibody Discovery Undisclosed Immuno‐oncology
Nogra Pharma Apr‐14 GED‐0301 Crohn’s disease
Abide Therapeutics Feb‐14 AB101131; Drug Discovery Inflammation; Immunology
NantBioScience Jan‐14 NTB‐011, NTB‐010; nab‐based molecules Cancer
OncoMed Dec‐13 Demicizumab; 6 anti‐CSC Products Solid tumors, NSCLC, Pancreatic
PharmAkea Oct‐13 Small‐molecule Discovery Cancer, Fibrotic disease
Adimab Aug‐13 Antibody Discovery Undisclosed
Acetylon Jul‐13 Ricolinostat; ACY‐738 Cancer; Hematology
Array Biopharma Jul‐13 Inflammation
Tengion Jul‐13 Neo-Kidney Augment Program CKD
Concert Pharma May‐13 CTP‐730 Inflammation
FORMA therapeutics Apr‐13 Protein Homeostasis
BlueBird Bio Mar-13 (+2) CAR‐T Cell BCMA Hematology
Presage Biosciences Mar‐13 Drug‐Discovery Platform Solid tumors
VentiRx Oct‐12 VTX‐2337 Solid tumors
InhibRx Jun‐12 Antibody Discovery Undisclosed
AnaptysBio Apr‐12 Antibody Discovery Cancer, Inflammation
Quanticel Pharmaceuticals Nov‐11 Cancer
Agios Apr-10 (+2) AG‐221, AG‐881 IDH2/pan Mutant Cancers
GlobeImmune May‐09 GI‐6301, GI‐6207, GI‐4000 Oncology
Acceleron Feb‐08 Sotatercept, Luspatercept Beta‐Thalassemia, MDS, CKD
Courtesy Michael Yee, RBC Capital Markets


And this is the slide from Celgene’s own deck showing off their partnering prowess:


Celgene 2016 JPM Presentation (pg 26)

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->